Live feed
Filing
SCHEDULE 13G
SCHEDULE 13G0000080255-25-000177·Celldex Therapeutics, Inc.
Schedule 13G ownership disclosure
Celldex Therapeutics Inc
COMMON STOCK · CUSIP: 15117B202
Event date: 2024-12-31
- Filing-level shares
- 3,557,136
- Percent of class
- 5.4%
- T. Rowe Price Associates, Inc.
Shares: 3,557,136 · Class: 5.4%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0000080255-25-000177
- Form type
- SCHEDULE 13G
- Filer
- Celldex Therapeutics, Inc.
- CIK
- CIK 744218
- Filed
- Feb 14, 2025
- Reporting period
- Dec 31, 2024
- Description
- Schedule 13G beneficial ownership